ERBB2 and breast carcinoma: Tumour shedding in advanced HER2+ breast cancer produces circulating exosomes containing HER2 extracellular domain (ECD) which can bind to and reduce the pharmacological effect of trastuzumab.55 Biological treatments, such as immunotherapies, carry the risk of developing anti-drug antibodies (ADAs).